NBL-020

Main purpose: To evaluate the safety and tolerability of NBL-020 injection in subjects with advanced malignant tumors, and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) (if any), recommended dose for Phase II (RP2D) and dosing regimen of NBL-020. Secondary purpose: 1) To evaluate the pharmacokinetic (PK) characteristics of NBL-020 injection in subjects with advanced malignant tumors. 2) To evaluate the preliminary anti-tumor activity of NBL-020 injection in subjects with advanced malignant tumors. 3) To evaluate the immunogenicity of NBL-020 injection in subjects with advanced malignant tumors. 4) To evaluate the pharmacodynamic (PD) indicators of NBL-020 injection.